Q1: 2026-04-22 Earnings Abstract
EPS of $4.28 beats by $0.32
| Income of $706.60M (26.50% Y/Y) beats by $8.97M
Medpace Holdings, Inc. (MEDP) Q1 2026 Earnings Name April 23, 2026 9:00 AM EDT
Firm Individuals
Lauren Morris – Affiliate Director of Traders Relations
August Troendle – Chairman & CEO
Jesse Geiger – President
Kevin Brady – CFO & Treasurer
Convention Name Individuals
Max Smock – William Blair & Firm L.L.C., Analysis Division
David Windley – Jefferies LLC, Analysis Division
Ann Hynes – Mizuho Securities USA LLC, Analysis Division
Charles Rhyee – TD Cowen, Analysis Division
Eric Coldwell – Robert W. Baird & Co. Integrated, Analysis Division
Jailendra Singh – Truist Securities, Inc., Analysis Division
Sean Dodge – BMO Capital Markets Fairness Analysis
Michael Cherny – Leerink Companions LLC, Analysis Division
Ryan Halsted – RBC Capital Markets, Analysis Division
Justin Bowers – Deutsche Financial institution AG, Analysis Division
Presentation
Operator
Good day, girls and gents, and welcome to the Medpace First Quarter 2026 Earnings Convention Name. [Operator Instructions] As a reminder, this name is being recorded.
I might now prefer to introduce your host for right now’s convention name, Lauren Morris, Medpace’s Director of Investor Relations. Chances are you’ll start.
Lauren Morris
Affiliate Director of Traders Relations
Good morning, and thanks for becoming a member of Medpace’s First Quarter 2026 Earnings Convention Name. Additionally on the decision right now is our CEO, August Troendle; our President, Jesse Geiger; and our CFO, Kevin Brady.
Earlier than we start, I wish to remind you that our remarks and responses to your questions throughout this teleconference could embrace forward-looking statements inside the which means of the Non-public Securities Litigation Reform Act of 1995. These statements contain inherent assumptions with identified and unknown dangers and uncertainties in addition to different essential components that would trigger precise outcomes to vary materially from our present expectations. These components are mentioned in our Kind 10-Okay and different filings with the SEC. Please word that we assume no obligation to replace forward-looking statements even when estimates change. Accordingly, you shouldn’t
